We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$28.5B
AUM Growth
+$2.42B
(+9.3%)
Cap. Flow
+$581M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
19.66%
Holding
1,921
New
171
Increased
1,320
Reduced
356
Closed
71
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$111M |
| 2 |
VF Corp
VFC
|
+$73.4M |
| 3 |
Amazon
AMZN
|
+$71M |
| 4 |
Stanley Black & Decker
SWK
|
+$60.2M |
| 5 |
Tesla
TSLA
|
+$46.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$158M |
| 2 |
Apple
AAPL
|
+$130M |
| 3 |
Cardinal Health
CAH
|
+$43.7M |
| 4 |
Fortinet
FTNT
|
+$39.6M |
| 5 |
ExxonMobil
XOM
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.73% |
| 2 | Industrials | 12.07% |
| 3 | Consumer Staples | 11.64% |
| 4 | Healthcare | 11.12% |
| 5 | Financials | 10.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Janus International
JBI
$722M
| $100K | ﹤0.01% |
+10,510
| New | +$101K |
|
1652
Vanda Pharmaceuticals
VNDA
$312M
| $99.3K | ﹤0.01% |
13,432
+1,014
| +8% | +$9.88K |
|
1653
Sweetgreen
SG
$713M
| $97.9K | ﹤0.01% |
+11,418
| New | +$166K |
|
|
ESPR
1654
DELISTED
Esperion Therapeutics
ESPR
| $97.1K | ﹤0.01% |
15,583
+2,643
| +20% | +$18.9K |
|
|
NKLA
1655
DELISTED
Nikola Corporation Common Stock
NKLA
| $96.8K | ﹤0.01% |
1,494
+362
| +32% | +$30.3K |
|
|
SGMO
1656
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $96.6K | ﹤0.01% |
30,772
+3,511
| +13% | +$13.6K |
|
1657
Tango Therapeutics
TNGX
$4.34B
| $96.4K | ﹤0.01% |
+13,293
| New | +$93.5K |
|
1658
Yext
YEXT
$501M
| $95.7K | ﹤0.01% |
14,653
+2,099
| +17% | +$11.4K |
|
1659
LegalZoom.com
LZ
$1.23B
| $95.5K | ﹤0.01% |
12,344
+1,769
| +17% | +$15.4K |
|
|
CHS
1660
DELISTED
Chicos FAS, Inc.
CHS
| $95.5K | ﹤0.01% |
19,404
+2,496
| +15% | +$14K |
|
1661
iHeartMedia
IHRT
$535M
| $95.1K | ﹤0.01% |
15,513
+2,224
| +17% | +$17.1K |
|
|
CVAC
1662
DELISTED
CureVac
CVAC
| $94.9K | ﹤0.01% |
15,738
-32
| -0.2% | -$236 |
|
1663
Sutro Biopharma
STRO
$379M
| $94.5K | ﹤0.01% |
+1,169
| New | +$81.2K |
|
|
AGEN
1664
Agenus
AGEN
$249M
| $94.1K | ﹤0.01% |
1,997
+408
| +26% | +$20.7K |
|
1665
ARKO Corp
ARKO
$890M
| $93K | ﹤0.01% |
+10,735
| New | +$99.4K |
|
1666
PureCycle Technologies
PCT
$1.17B
| $92.4K | ﹤0.01% |
13,673
+1,959
| +17% | +$14.1K |
|
|
LPRO
1667
Open Lending Corp
LPRO
$373M
| $91.6K | ﹤0.01% |
13,575
+1,946
| +17% | +$13.7K |
|
1668
Repay Holdings
RPAY
$315M
| $90.8K | ﹤0.01% |
+11,274
| New | +$81.1K |
|
1669
Edgewise Therapeutics
EWTX
$4.39B
| $90.3K | ﹤0.01% |
+10,105
| New | +$94.7K |
|
1670
SIGA Technologies
SIGA
$223M
| $89.1K | ﹤0.01% |
12,100
+758
| +7% | +$6.64K |
|
|
PAYA
1671
DELISTED
Paya Holdings Inc. Class A Common Stock
PAYA
| $88.6K | ﹤0.01% |
+11,260
| New | +$86.9K |
|
1672
Conduent
CNDT
$230M
| $88.5K | ﹤0.01% |
21,846
+3,131
| +17% | +$12K |
|
|
KZR
1673
DELISTED
Kezar Life Sciences
KZR
| $87.5K | ﹤0.01% |
1,243
+88
| +8% | +$6.53K |
|
|
SAFE
1674
Safehold
SAFE
$1.19B
| $87.4K | ﹤0.01% |
+1,832
| New | +$88.3K |
|
1675
Planet Labs
PL
$7.3B
| $87K | ﹤0.01% |
20,008
+2,867
| +17% | +$14.8K |
|
Similar funds
ProShare Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, ProShare Advisors held 1,921 positions worth $28.5B, up 9.3% from $26.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
ProShare Advisors's Q4 2022 filing shows 171 new, 1,320 increased, 356 reduced and 71 closed positions. Its largest new stake was Rivian: 689,839 shares worth $12.7M. The largest sale was Target, an estimated $158M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.
- ProShare Advisors's largest Q4 2022 buy was Rivian: 689,839 shares worth $12.7M.
- ProShare Advisors added most to Microsoft in Q4 2022, an estimated $111M increase.
- ProShare Advisors's biggest Q4 2022 reduction was Apple, cutting an estimated $130M.
- ProShare Advisors fully exited Target in Q4 2022, selling an estimated $158M.
- ProShare Advisors's ten largest holdings make up 20% of its $28.5B portfolio in Q4 2022.
- ProShare Advisors opened 171 new positions and closed 71 in Q4 2022.
- ProShare Advisors's portfolio value rose 9.3% quarter-over-quarter to $28.5B.
Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.